Sanofi-Aventis BSI-201 Phase II setback could be PARP party-pooper
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis' PARP inhibitor, BSI-201 (iniparib) has missed its primary endpoints - overall survival after 18 months and progression-free survival in a 12 month timeframe - in its most advanced clinical study with the compound, a phase III trial in around 400 patients with metastatic triple-negative breast cancer. As the most advanced trial of any PARP inhibitor, the result may raise questions for companies such as AstraZeneca, Abbott, and Pfizer, whose PARP inhibitors are in phase II trial for various solid-tumour indications